News

Start of the Magnetic Resonance Outcome (MRO) study to evaluate the ClearCoast™ MRI system

The ClearCoast™ MRI system makes it possible to perform precise intraoperative margin evaluation during breast-conserving surgery – often eliminating the need for the patient to undergo a second operation. In the MRO study, launched in June 2021, surgeons are able for the first time to evaluate the tissue margin during the operation. The aim: to reduce the rate of second operations by 80 percent. Being able to evaluate the margin quickly and...

New name: ClearSight™ has become ClearCoast™

ClearCut Medical Ltd. has changed the name of its diffusion-weighted MRI technology for intraoperative margin evaluation, previously known as the ClearSight™ system – with immediate effect. This product is now called the ClearCoast™ MRI system. The name change was made due to trademark issues. The containers for the tissue excised during surgery have also been renamed – they are now called ClearCoast™ Tissue Containers. Despite the new names, the...

pfm Forceps EWF 600 - The first wireless electronic forceps for the histologic lab is now available

Cologne, 22 January 2020 - At the end of January, pfm medical ag will be adding 3 new products to its histotechnology product portfolio: The manual microtome pfm Rotary 3000 Compact, the pfm Cooling Plate TES 5010 and the wireless heated pfm Forceps EWF 600. The products will be presented for the first time in Germany at the 22nd Bamberg Morphology Days, 24-26th January 2020. The pfm Forceps EWF 600 are a new addition to the pfm medical ag...

pfm medical expands portfolio in breast cancer diagnostics through agreement with portable MRI pioneer ClearCut Medical

Israeli medical technology start-up ClearCut Medical has granted pfm medical exclusive European distribution rights for the innovative ClearSight™ system. With the ClearSight™ system, the Cologne-based medical technology company is expanding its breast surgery portfolio with a groundbreaking method for accurate margin evaluation in breast cancer. By enabling the performance of magnetic resonance imaging in an intraoperative environment, the...

Growth in CVT portfolio: pfm medical becomes exclusive distributer for EmeryGlide from Nano4Imaging

pfm medical is expanding its cardiovascular product portfolio with the EmeryGlide MR conditional guidewire from Nano4Imaging. The two companies announced their future cooperation at the AEPC Congress in Seville. pfm medical has been successful with its products in the field of cardiovascular therapies both nationally and internationally for many years, especially in interventional pediatric cardiology. With the EmeryGlide pfm medical expands this...

Period

Start of the Magnetic Resonance Outcome (MRO) study to evaluate the ClearCoast™ MRI system

New name: ClearSight™ has become ClearCoast™

pfm Forceps EWF 600 - The first wireless electronic forceps for the histologic lab is now available

pfm medical expands portfolio in breast cancer diagnostics through agreement with portable MRI pioneer ClearCut Medical

Growth in CVT portfolio: pfm medical becomes exclusive distributer for EmeryGlide from Nano4Imaging